Working with its clients to ensure a successful outcome in terms of market access, Grove consultants provide expert advice in three key areas:
Good logistics and increasing levels of transparency relative to that which existed historically, now characterize the Czech healthcare system. In part, this has been driven by recent changes to the reimbursement and healthcare purchasing systems implemented as part of a government drive to make the Czech public health insurance system more effective. However, the fact remains that the local pricing and reimbursement system remains complex and cumbersome.
Although challenging to navigate, the reimbursement system today is at least driven by clear bureaucratic procedures. With this, comes predictability.
With a unique referencing system and continual price pressures which afford manufacturers clear challenges, the local regulatory framework is noted for its ability to provide patients access to new medicines. This in itself, makes the market an attractive option for many.
While the Ministry of Health has some influence, it is the State Institute for Drug Control (SUKL) that plays the major role and is the interface with manufacturers as far as pricing and reimbursement are concerned within the market for medicines, medical devices, food supplements and cosmetics.
Only with an understanding of the reimbursement policy in the Czech Republic, can new market entrants hope to get their own price and reimbursement strategies and subsequent reimbursement application right. With experienced local consultants, Grove can assist with: